Is Hydroxyzine Really a Sleeping Pill? What to Know

Hydroxyzine is not a sleeping pill in any official sense. It has never been approved by the FDA for treating insomnia. What it is, formally, is a first-generation antihistamine that has been on the market since 1956, cleared for treating anxiety, itching, and sedation before surgery. The drowsiness it reliably produces is a side effect, and that side effect is exactly why doctors write millions of off-label prescriptions for it as a sleep aid. But the evidence that it actually improves sleep in a meaningful, sustained way turns out to be remarkably thin.

What Hydroxyzine Is Approved For

Hydroxyzine comes in two salt forms. One (hydrochloride, originally branded Atarax) is available as tablets; the other (pamoate, originally branded Vistaril) comes in capsules. Both are the same active molecule. The FDA’s approved indications include symptomatic relief of anxiety, relief of itching caused by allergic conditions, and sedation before or after general anesthesia. None of those indications mention insomnia. That distinction matters because when a drug is prescribed off-label, it means the prescribing clinician is making a judgment call based on the drug’s known pharmacology and their clinical experience rather than on a body of evidence the FDA has formally reviewed for that purpose.

Hydroxyzine works by blocking histamine H1 receptors in the brain. Histamine is one of the chemicals your brain uses to keep you alert, which is why blocking it makes you drowsy. This is the same mechanism behind the sleepiness you feel after taking diphenhydramine (Benadryl) or doxylamine (the active ingredient in many over-the-counter sleep aids). Hydroxyzine also has anticholinergic properties, meaning it blocks another signaling molecule called acetylcholine. That secondary action contributes to some of its side effects, which become a more serious concern for certain groups of people.

How Weak the Sleep Evidence Actually Is

Given how commonly hydroxyzine is prescribed for sleep, you might assume there is a solid stack of clinical trials backing that use. There is not. A 2023 systematic review searched the medical literature for every study examining hydroxyzine’s effectiveness as a sleep aid in adults. The researchers found only five studies that qualified for inclusion: one open-label trial and four randomized controlled trials, covering a total of just 207 patients. The doses tested ranged from 25 mg to 100 mg at bedtime. Across those studies, the results on whether hydroxyzine actually helped people fall asleep faster, stay asleep longer, or sleep more deeply were mixed, meaning some measures improved in some studies but not consistently across the board.¹

To put 207 patients across five studies in perspective, that is an extraordinarily small evidence base for a drug that has been available for nearly seven decades and is prescribed to vast numbers of people for this exact purpose. By comparison, commonly used prescription sleep medications went through trials involving thousands of participants before gaining FDA approval for insomnia. The systematic review did not conclude that hydroxyzine is useless for sleep, but it did not find strong, consistent evidence that it works well, either. For a medication that many people assume is a proven sleep aid, this gap between reputation and evidence is striking.

Why It Gets Prescribed for Sleep Anyway

If the sleep evidence is so sparse, why do so many doctors reach for hydroxyzine at bedtime? Several practical factors drive its popularity. First, hydroxyzine is not a controlled substance. Benzodiazepines (like lorazepam or temazepam) and newer Z-drugs (like zolpidem) are Schedule IV controlled substances, meaning they carry regulatory requirements for prescribing, refills, and monitoring. Hydroxyzine sidesteps all of that. A doctor can prescribe it with fewer bureaucratic hoops, and patients do not face the stigma or logistical hassle associated with controlled medications.

Second, hydroxyzine does reliably produce sedation. Clinicians observe it in practice every day. The issue is not that it fails to make people drowsy; it unquestionably does. The question is whether that drowsiness translates into genuinely better, more restorative sleep, or whether it simply knocks people out without improving the quality of the sleep they get. The studies available so far have not answered that question convincingly.

Third, and perhaps most importantly, hydroxyzine has an FDA-approved indication for anxiety, and anxiety is one of the most common drivers of insomnia. When a patient cannot sleep because their mind is racing, an anxiolytic that also causes drowsiness seems like a logical two-for-one solution. In that context, many clinicians view hydroxyzine as treating the root cause (anxiety) with a welcome side benefit (sedation) rather than using it as a standalone sleep drug. Whether that framing holds up under scrutiny depends on how much of the insomnia is truly anxiety-driven, which varies enormously from person to person.

Side Effects Worth Taking Seriously

The most commonly reported side effect in the sleep studies was dry mouth, which is directly related to hydroxyzine’s anticholinergic activity.¹ But dry mouth is the mild end of the anticholinergic spectrum. Other anticholinergic effects include constipation, blurred vision, urinary retention, and cognitive impairment. That last one is especially concerning because it can be subtle, showing up as difficulty concentrating, memory lapses, or a foggy feeling the next day, exactly the kind of cognitive blunting you would not want from something supposed to help you function better by improving your sleep.

The systematic review also noted a troubling gap in safety reporting: four of the five included studies did not formally report safety outcomes at all.¹ That is not reassuring. It does not mean hydroxyzine is dangerous, but it does mean the limited data we have on its effectiveness is accompanied by even less data on its risks when used specifically as a sleep aid.

In terms of overdose safety, hydroxyzine does appear to have a somewhat better profile than its cousin diphenhydramine. A cohort analysis comparing overdose cases found that hydroxyzine-poisoned patients had lower rates of severe antimuscarinic effects compared to diphenhydramine-poisoned patients, including lower rates of coma, respiratory depression, seizures, and serious cardiac rhythm disturbances. Mortality from hydroxyzine overdose was rare, reported at 0.02% in one national database and 0.8% in another.² That relative safety in overdose is one of the reasons some prescribers consider it a lower-risk option, particularly for patients with a history of suicidal ideation, where prescribing a medication with a wide margin of safety matters.

The Heart Rhythm Question

One safety concern that prompted regulatory action in some countries involves hydroxyzine’s potential to affect the heart’s electrical activity. Specifically, it can prolong the QT interval, a measure of how long it takes the heart’s electrical system to recharge between beats. An excessively prolonged QT interval can, in rare cases, trigger a dangerous heart rhythm called torsade de pointes.

A review of hydroxyzine’s global safety database from 1955 through 2016 identified 59 case reports of QT prolongation or torsade de pointes. Every one of those 59 cases involved patients who already had at least one existing risk factor, such as underlying heart disease, electrolyte imbalances, the use of other QT-prolonging medications, or intentional overdose.³ In other words, this does not appear to be a risk that materializes in otherwise healthy people taking normal doses. But it does mean hydroxyzine warrants caution in anyone already at risk for QT prolongation, including people taking certain antidepressants, antipsychotics, or antibiotics that carry the same cardiac warning. The European Medicines Agency responded to this data by recommending dose limits and contraindications for patients with known risk factors.

Why It’s Flagged as Risky for Older Adults

The American Geriatrics Society publishes a widely used list called the Beers Criteria, which identifies medications that are generally best avoided in adults 65 and older. Hydroxyzine appears on that list due to its anticholinergic properties. In older adults, anticholinergic drugs are linked to an increased risk of confusion, sedation, cognitive decline, and falls.⁴ The aging brain is more sensitive to anticholinergic effects, and the drug’s sedating properties, which younger patients may tolerate as manageable drowsiness, can in older adults become disorientation and impaired balance.

Despite this guidance, hydroxyzine remains commonly used in elderly care settings. A cross-sectional study of nursing home residents with dementia found that among all residents prescribed at least one anticholinergic drug, hydroxyzine and similar antihistamines accounted for nearly 60% of that anticholinergic drug use.⁵ The irony is hard to miss: a drug flagged as potentially inappropriate for older adults because of its cognitive effects is being widely used in patients who already have cognitive impairment. This pattern likely reflects the limited options available in these settings and the practical pressure to manage agitation and sleeplessness in dementia patients, but it highlights how prescribing for sleep can drift into territory the evidence does not support.

If you are over 65 and your doctor suggests hydroxyzine for sleep, it is worth having a direct conversation about why it was chosen over alternatives that are not on the Beers list. Some insurers now require prior authorization for hydroxyzine in older adults specifically because of these concerns, which can add another layer of friction to its use in this population.

Hydroxyzine in Children

Antihistamines like hydroxyzine and diphenhydramine are the most widely prescribed sedatives in pediatric practice, yet the evidence supporting their use in children remains limited.⁶ This is a familiar pattern: widespread clinical use running ahead of the evidence base. Hydroxyzine is sometimes prescribed for children with sleep difficulties, particularly those with neurodevelopmental conditions like autism spectrum disorder, where sleep problems are common and difficult to manage.

A large population-based longitudinal study added a note of caution to this practice. Researchers tracked preschool-aged children who were prescribed hydroxyzine and followed them through age 10, comparing outcomes across different levels of exposure. Children who used hydroxyzine more frequently showed higher rates of tic disorders, anxiety diagnoses, and conduct disturbances compared to short-term users. After adjusting for demographic factors, frequent hydroxyzine use was associated with roughly 30% to 45% higher odds of these conditions compared to short-term use.⁷

This kind of observational finding does not prove that hydroxyzine caused those outcomes. Children prescribed hydroxyzine more frequently may have had underlying conditions that predisposed them to these diagnoses regardless of medication use. But the study raises legitimate questions about long-term use of anticholinergic medications in developing brains, and it underscores how little is known about the downstream effects of using hydroxyzine as a routine sleep aid in young children.

What Tolerance Looks Like in Practice

One experience nearly everyone who uses hydroxyzine for sleep will encounter is that it stops working as well over time. This is a well-recognized feature of first-generation antihistamines as a class. Your brain adjusts to the blockade of histamine receptors, and the same dose that initially produced reliable drowsiness gradually loses its punch. Most people notice the effect within a few weeks. The typical response, predictably, is to increase the dose, but that brings more anticholinergic side effects without necessarily restoring the original level of sedation.

This tolerance issue is one of the fundamental reasons hydroxyzine is poorly suited as a long-term sleep aid. A drug that requires escalating doses to maintain effect while simultaneously accumulating side-effect burden is not a sustainable solution. It may work well as a short-term bridge, helping someone sleep during a particularly anxious stretch, a stressful life event, or a period of acute insomnia while other interventions take hold. But treating it as an indefinite nightly sleep aid is a setup for diminishing returns.

How It Compares to Dedicated Sleep Treatments

The gold standard for chronic insomnia treatment is not a pill at all. Cognitive behavioral therapy for insomnia (CBT-I) is recommended as the first-line treatment by every major sleep medicine guideline. It is a structured program that addresses the thoughts and behaviors perpetuating poor sleep, including sleep restriction, stimulus control, and relaxation techniques. The effects tend to be durable, meaning they persist long after treatment ends, which is something no sedating medication can claim.

Among medications, the landscape for insomnia includes several categories. Newer dual orexin receptor antagonists (like suvorexant and lemborexant) work by a completely different mechanism than antihistamines, targeting the wakefulness-promoting orexin system. Low-dose doxepin, a tricyclic antidepressant, is FDA-approved specifically for sleep maintenance insomnia at much lower doses than those used for depression. Extended-release melatonin and ramelteon target the circadian system. Each of these has been studied in the kinds of large, well-designed trials that hydroxyzine lacks for the insomnia indication.

Where hydroxyzine sometimes fits in the real-world prescribing toolkit is in patients with co-occurring anxiety and insomnia who cannot tolerate or do not want benzodiazepines, who have substance use histories that make controlled substances risky, or who need short-term sedation while starting an SSRI (which can temporarily worsen insomnia in the first few weeks). In those scenarios, hydroxyzine’s anxiolytic and sedative effects together can serve as a pragmatic short-term bridge. The problem is when “short-term bridge” quietly becomes “nightly routine for years.”

The Next-Day Hangover Effect

Hydroxyzine’s half-life in adults is roughly 20 hours, though it varies. That means if you take it at bedtime, a substantial amount is still circulating when you wake up. Many people experience this as grogginess, sluggishness, or difficulty concentrating the next morning, sometimes well into the afternoon. For someone who took hydroxyzine hoping to sleep better so they could function better the next day, a persistent sedation hangover is counterproductive.

This residual sedation also has real-world safety implications. Driving performance, reaction time, and judgment can all be impaired. First-generation antihistamines as a class have been associated with increased motor vehicle accident risk, a fact that is often overlooked when these drugs are casually prescribed or taken over the counter. If you find yourself needing coffee just to shake off the fog from last night’s hydroxyzine, the drug may be trading one problem (poor sleep) for another (impaired daytime function).

Shorter-acting alternatives, whether prescription or behavioral, can offer the sleep benefit without the next-day penalty. If residual sedation is an issue for you, bringing it up with your prescriber can open a conversation about whether the current approach is actually netting you a benefit or just shifting the burden from nighttime to daytime.